Neurological Complications of Plasma Cell Disorders

Chapter

Abstract

Plasma cell disorders include monoclonal gammopathies of unknown significance, multiple myeloma, plasmacytoma, Waldenstrom’s macroglobulinemia, and amyloidosis. This group of neoplastic diseases involves proliferation of a single clone of plasma cells, producing a monoclonal immunoglobulin protein or immunoglobulin fragment (M protein) that can be identified as a spike on electrophoresis of serum or urine. Plasma cell disorders are associated with a wide spectrum of neurological complications. The pathophysiology, diagnosis, and management of these neurological complications are the subject of this review.

Keywords

Doxorubicin Tamoxifen Cyclophosphamide Myeloma Constipation 

References

  1. 1.
    Dispenzieri A, Kyle RA (2005) Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 18:673–688PubMedCrossRefGoogle Scholar
  2. 2.
    Spinazze S, Caraceni A, Schrijvers D (2005) Epidural spinal cord compression. Crit Rev Oncol Hematol 56:397–406PubMedCrossRefGoogle Scholar
  3. 3.
    Maghfoor I, Perry MC (2000) Malignancy: meningeal myeloma: a case report and review of literature. Hematology 5:47–52PubMedGoogle Scholar
  4. 4.
    Roddie P, Collie D, Johnson P (2000) Myelomatous involvement of the dura mater: a rare complication of multiple myeloma. J Clin Pathol 53:398–399PubMedCrossRefGoogle Scholar
  5. 5.
    Savage DG, Mears JG, Balmaceda C et al (2002) Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation. Leuk Res 26:689–692PubMedCrossRefGoogle Scholar
  6. 6.
    Slager UT, Taylor WF, Opfell RW, Myers A (1979) Leptomeningeal myeloma. Arch Pathol Lab Med 103:680–682PubMedGoogle Scholar
  7. 7.
    Oyajobi BO (2007) Multiple myeloma/hypercalcemia. Arthritis Res Ther 9(Suppl 1):S4PubMedCrossRefGoogle Scholar
  8. 8.
    Mehta J, Singhal S (2003) Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 29:467–471PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson SA, Oscier DG, Leblond V (2002) Waldenstrom’s macroglobulinaemia. Blood Rev 16:175–184PubMedCrossRefGoogle Scholar
  10. 10.
    Preston FE, Cooke KB, Foster ME et al (1978) Myelomatosis and the hyperviscosity syndrome. Br J Haematol 38:517–530PubMedCrossRefGoogle Scholar
  11. 11.
    Pruzanski W, Watt JG (1972) Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. Ann Intern Med 77:853–860PubMedGoogle Scholar
  12. 12.
    Adams BD, Baker R, Lopez JA, Spencer S (2009) Myeloproliferative disorders and the hyperviscosity syndrome. Emerg Med Clin North Am 27:459–476PubMedCrossRefGoogle Scholar
  13. 13.
    Pavy MD, Murphy PL, Virella G (1980) Paraprotein-induced hyperviscosity. A reversible cause of stroke. Postgrad Med 68:109–112PubMedGoogle Scholar
  14. 14.
    Stone MJ (2009) Waldenstrom’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 9:97–99PubMedCrossRefGoogle Scholar
  15. 15.
    Bernard A, Rousselie F (1986) Macular manifestations of monoclonal dysgammaglobulinemias. Apropos of 3 cases. J Fr Ophthalmol 9:805–810Google Scholar
  16. 16.
    Alatoom A, Elsabrouty R, Willis J et al (2009) Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia. Int J Clin Exp Pathol 2:498–507PubMedGoogle Scholar
  17. 17.
    Chen C, Kouroukis CT, White D et al (2009) Bortezomib in relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma 9:74–76PubMedCrossRefGoogle Scholar
  18. 18.
    Dimopoulos MA, Gertz MA, Kastritis E et al (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol 27:120–126PubMedCrossRefGoogle Scholar
  19. 19.
    Treon SP (2009) How I treat Waldenstrom macroglobulinemia. Blood 114:2375–2385PubMedCrossRefGoogle Scholar
  20. 20.
    Bing JN, Fog M, Neel AV (1937) Report of a third case of hyperglobulinemia with affection of the central nervous system on a toxi-infectious basis, and some remarks on the differential diagnosis. Acta Med. Scand 91:409–427CrossRefGoogle Scholar
  21. 21.
    Fintelmann F, Forghani R, Schaefer PW et al (2009) Bing-Neel syndrome revisited. Clin Lymphoma Myeloma 9:104–106PubMedCrossRefGoogle Scholar
  22. 22.
    Edgar R, Dutcher TF (1961) Histopathology of the Bing-Neel syndrome. Neurology 11:239–245PubMedGoogle Scholar
  23. 23.
    Grewal JS, Brar PK, Sahijdak WM et al (2009) Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options. Clin Lymphoma Myeloma 9:462–466PubMedCrossRefGoogle Scholar
  24. 24.
    Malkani RG, Tallman M, Gottardi-Littell N et al (2009) Bing-Neel syndrome: an illustrative case and a comprehensive review of the published literature. J Neurooncol 96(3):301–312PubMedCrossRefGoogle Scholar
  25. 25.
    Welch D, Whetsell WO Jr., Weil RJ (2002) Pathologic quiz case. A man with long-standing monoclonal gammopathy and new onset of confusion. Central nervous system involvement by Waldenstrom macroglobulinemia-Bing-Neel syndrome. Arch Pathol Lab Med 126:1243–1244PubMedGoogle Scholar
  26. 26.
    Drappatz J, Akar S, Fisher DC et al (2008) Imaging of Bing-Neel syndrome. Neurology 70:1364PubMedCrossRefGoogle Scholar
  27. 27.
    Fassas AB, Ward S, Muwalla F et al (2004) Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 45:291–300PubMedCrossRefGoogle Scholar
  28. 28.
    Nieuwenhuizen L, Biesma DH (2008) Central nervous system myelomatosis: review of the literature. Eur J Haematol 80:1–9PubMedGoogle Scholar
  29. 29.
    Dennis M, Chu P (2000) A case of meningeal myeloma presenting as obstructive hydrocephalus – a therapeutic challenge. Leuk Lymphoma 40:219–220PubMedCrossRefGoogle Scholar
  30. 30.
    Pontikoglou C, Fragos C, Kolyvaki E et al (2005) Multiple myeloma involving the central nervous system: a report of two cases with unusual manifestations. Leuk Lymphoma 46:737–741PubMedCrossRefGoogle Scholar
  31. 31.
    Quach H, Ryan G, Ganju V, Prince HM (2005) Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion. Bone Marrow Transplant 35:423–424PubMedCrossRefGoogle Scholar
  32. 32.
    Veinstein A, Brizard A, Randriamalala E et al (1997) Central nervous system relapses after autologous stem cell transplantation for myeloma. Report of two cases. Hematol Cell Ther 39:327–330PubMedCrossRefGoogle Scholar
  33. 33.
    Hogan MC, Lee A, Solberg LA, Thome SD (2002) Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol 70:55–59PubMedCrossRefGoogle Scholar
  34. 34.
    Knapp AJ, Gartner S, Henkind P (1987) Multiple myeloma and its ocular manifestations. Surv Ophthalmol 31:343–351PubMedCrossRefGoogle Scholar
  35. 35.
    Shone GR (1985) Facial palsy due to myeloma of the temporal bone. J Laryngol Otol 99:907–908PubMedCrossRefGoogle Scholar
  36. 36.
    Witt C, Borges AC, Klein K, Neumann HJ (1997) Radiographic manifestations of multiple myeloma in the mandible: a retrospective study of 77 patients. J Oral Maxillofac Surg 55:450–453; discussion 454–455PubMedCrossRefGoogle Scholar
  37. 37.
    Colak A, Cataltepe O, Ozgen T, Erbengi A (1989) Spinal cord compression caused by plasmacytomas. A retrospective review of 14 cases. Neurosurg Rev 12:305–308PubMedCrossRefGoogle Scholar
  38. 38.
    Spiess JL, Adelstein DJ, Hines JD (1988) Multiple myeloma presenting with spinal cord compression. Oncology 45:88–92PubMedCrossRefGoogle Scholar
  39. 39.
    Schiff D (2003) Spinal cord compression. Neurol Clin 21:67–86PubMedCrossRefGoogle Scholar
  40. 40.
    Young RF, Post EM, King GA (1980) Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 53:741–748PubMedCrossRefGoogle Scholar
  41. 41.
    Patchell RA, Tibbs PA, Regine WF et al (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643–648PubMedCrossRefGoogle Scholar
  42. 42.
    Witham TF, Khavkin YA, Gallia GL et al (2006) Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol 2:87–94; quiz 116PubMedCrossRefGoogle Scholar
  43. 43.
    Sun H, Nemecek AN (2009) Optimal management of malignant epidural spinal cord compression. Emerg Med Clin North Am 27:195–208PubMedCrossRefGoogle Scholar
  44. 44.
    Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRefGoogle Scholar
  45. 45.
    Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33PubMedCrossRefGoogle Scholar
  46. 46.
    Mundy GR (1998) Myeloma bone disease. Eur J Cancer 34:246–251PubMedCrossRefGoogle Scholar
  47. 47.
    Riggs JE (2002) Neurologic manifestations of electrolyte disturbances. Neurol Clin 20:227–239PubMedCrossRefGoogle Scholar
  48. 48.
    Nobile-Orazio E, Barbieri S, Baldini L et al (1992) Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 85:383–390PubMedCrossRefGoogle Scholar
  49. 49.
    Vrethem M, Cruz M, Wen-Xin H et al (1993) Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 114:193–199PubMedCrossRefGoogle Scholar
  50. 50.
    Silverstein A, Doniger DE (1963) Neurologic complications of myelomatosis. Arch Neurol 9:534–544PubMedGoogle Scholar
  51. 51.
    Walsh JC (1971) The neuropathy of multiple myeloma. An electrophysiological and histological study. Arch Neurol 25:404–414PubMedGoogle Scholar
  52. 52.
    Richardson PG, Xie W, Mitsiades C et al (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518–3525PubMedCrossRefGoogle Scholar
  53. 53.
    Kelly JJ Jr., Kyle RA, O‘Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31:1480–1483PubMedGoogle Scholar
  54. 54.
    Ramchandren S, Lewis RA (2009) Monoclonal gammopathy and neuropathy. Curr Opin Neurol 22:480–485PubMedCrossRefGoogle Scholar
  55. 55.
    Latov N, Braun PE, Gross RB et al (1981) Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci USA 78:7139–7142PubMedCrossRefGoogle Scholar
  56. 56.
    Latov N, Hays AP, Sherman WH (1988) Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 3:301–332PubMedGoogle Scholar
  57. 57.
    Ellie E, Vital A, Steck A et al (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 243:34–43PubMedCrossRefGoogle Scholar
  58. 58.
    Yeung KB, Thomas PK, King RH et al (1991) The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 238:383–391PubMedCrossRefGoogle Scholar
  59. 59.
    Drappatz J, Batchelor T (2004) Neurologic complications of plasma cell disorders. Clin Lymphoma 5:163–171PubMedCrossRefGoogle Scholar
  60. 60.
    Eurelings M, Moons KG, Notermans NC et al (2001) Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology 56:228–233PubMedGoogle Scholar
  61. 61.
    Nobile-Orazio E, Carpo M (2001) Neuropathy and monoclonal gammopathy. Curr Opin Neurol 14:615–620PubMedCrossRefGoogle Scholar
  62. 62.
    Zivkovic SA, Lacomis D, Lentzsch S (2009) Paraproteinemic neuropathy. Leuk Lymphoma 50:1422–1433PubMedCrossRefGoogle Scholar
  63. 63.
    Lunn MP, Nobile-Orazio E (2003) Immunotherapy for IgM anti-Myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 1:CD002827PubMedGoogle Scholar
  64. 64.
    Pestronk A, Florence J, Miller T et al (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485–489PubMedCrossRefGoogle Scholar
  65. 65.
    Dalakas MC, Rakocevic G, Salajegheh M et al (2009) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65:286–293PubMedCrossRefGoogle Scholar
  66. 66.
    Vrethem M, Reiser N, Lauermann C, Svanborg E (2009) Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings. Acta Neurol Scand 122(1):52–57PubMedCrossRefGoogle Scholar
  67. 67.
    Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772PubMedCrossRefGoogle Scholar
  68. 68.
    Wicklund MP, Kissel JT (2001) Paraproteinemic neuropathy. Curr Treat Options Neurol 3:147–156PubMedCrossRefGoogle Scholar
  69. 69.
    Hadden RD, Nobile-Orazio E, Sommer C et al (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13:809–818PubMedCrossRefGoogle Scholar
  70. 70.
    Victor M, Banker BQ, Adams RD (1958) The neuropathy of multiple myeloma. J Neurol Neurosurg Psychiatry 21:73–88PubMedCrossRefGoogle Scholar
  71. 71.
    Briemberg HR, Amato AA (2003) Neuromuscular complications of cancer. Neurol Clin 21:141–165PubMedCrossRefGoogle Scholar
  72. 72.
    Nakanishi T, Sobue I, Toyokura Y et al (1984) The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 34:712–720PubMedGoogle Scholar
  73. 73.
    Kelly JJ Jr., Kyle RA, Miles JM, Dyck PJ (1983) Osteosclerotic myeloma and peripheral neuropathy. Neurology 33:202–210PubMedGoogle Scholar
  74. 74.
    Kuwabara S, Misawa S, Kanai K et al (2008) Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 79:1255–1257PubMedCrossRefGoogle Scholar
  75. 75.
    Steck AJ, Czaplinski A, Renaud S (2008) Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update. Neurotherapeutics 5:528–534PubMedCrossRefGoogle Scholar
  76. 76.
    Creange A, Chater A, Brouet JC et al (2008) A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol 4:686–691PubMedCrossRefGoogle Scholar
  77. 77.
    Gupta S, Rana V, Chandra D et al (2006) Autologous peripheral stem cell transplant for POEMS syndrome: a case report. Hematology 11:361–363PubMedCrossRefGoogle Scholar
  78. 78.
    Mahdi-Rogers M, Kazmi M, Ferner R et al (2009) Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst 14:118–124PubMedCrossRefGoogle Scholar
  79. 79.
    Plasmati R, Pastorelli F, Cavo M et al (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573–581PubMedCrossRefGoogle Scholar
  80. 80.
    Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120PubMedCrossRefGoogle Scholar
  81. 81.
    Julien J, Vital C, Vallat JM et al (1978) Polyneuropathy in Waldenstrom’s macroglobulinemia. Deposition of M component on myelin sheaths. Arch Neurol 35:423–425PubMedGoogle Scholar
  82. 82.
    Rudnicki SA, Harik SI, Dhodapkar M et al (1998) Nervous system dysfunction in Waldenstrom’s macroglobulinemia: response to treatment. Neurology 51:1210–1213PubMedGoogle Scholar
  83. 83.
    Vital C, Deminiere C, Bourgouin B et al (1985) Waldenstrom’s macroglobulinemia and peripheral neuropathy: deposition of M-component and kappa light chain in the endoneurium. Neurology 35:603–606PubMedGoogle Scholar
  84. 84.
    Adams D (2001) Hereditary and acquired amyloid neuropathies. J Neurol 248:647–657PubMedCrossRefGoogle Scholar
  85. 85.
    Kyle RA, Greipp PR (1983) Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665–683PubMedGoogle Scholar
  86. 86.
    Bloch KJ, Franklin E (1982) Plasma cell dyscrasias and cryoglobulins. JAMA 248:2670–2676PubMedCrossRefGoogle Scholar
  87. 87.
    Garcia-Bragado F, Fernandez JM, Navarro C et al (1988) Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 45:1210–1214PubMedGoogle Scholar
  88. 88.
    Nemni R, Corbo M, Fazio R et al (1988) Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 111(Pt 3):541–552PubMedCrossRefGoogle Scholar
  89. 89.
    Vernino S, Wolfe GI (2007) Antibody testing in peripheral neuropathies. Neurol Clin 25:29–46PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of NeurologyHarvard Medical School, Center for Neuro-Oncology, Dana Farber Cancer Institute, Brigham and Women’s HospitalBostonUSA
  2. 2.Departments of Oncology and NeurologyMayo Clinic JacksonvilleJacksonvilleUSA

Personalised recommendations